Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Mar;38(3):547–557. doi: 10.1128/aac.38.3.547

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

M P Fink 1, D R Snydman 1, M S Niederman 1, K V Leeper Jr 1, R H Johnson 1, S O Heard 1, R G Wunderink 1, J W Caldwell 1, J J Schentag 1, G A Siami 1, et al.
PMCID: PMC284496  PMID: 8203853

Abstract

Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia. In this prospective, randomized, double-blind, multicenter trial, which included an intent-to-treat analysis, a total of 405 patients with severe pneumonia were enrolled. The mean APACHE II score was 17.6, 79% of the patients required mechanical ventilation, and 78% had nosocomial pneumonia. A subgroup of 205 patients (98 ciprofloxacin-treated patients and 107 imipenem-treated patients) were evaluable for the major efficacy endpoints. Patients were randomized to receive intravenous treatment with either ciprofloxacin (400 mg every 8 h) or imipenem (1,000 mg every 8 h), and doses were adjusted for renal function. The primary and secondary efficacy endpoints were bacteriological and clinical responses at 3 to 7 days after completion of therapy. Ciprofloxacin-treated patients had a higher bacteriological eradication rate than did imipenem-treated patients (69 versus 59%; 95% confidence interval of -0.6%, 26.2%; P = 0.069) and also a significantly higher clinical response rate (69 versus 56%; 95% confidence interval of 3.5%, 28.5%; P = 0.021). The greatest difference between ciprofloxacin and imipenem was in eradication of members of the family Enterobacteriaceae (93 versus 65%; P = 0.009). Stepwise logistic regression analysis demonstrated the following factors to be associated with bacteriological eradication: absence of Pseudomonas aeruginosa (P < 0.01), higher weight (P < 0.01), a low APACHE II score (P = 0.03), and treatment with ciprofloxacin (P = 0.04). When P. aeruginosa was recovered from initial respiratory tract cultures, failure to achieve bacteriological eradication and development of resistance during therapy were common in both treatment groups (67 and 33% for ciprofloxacin and 59 and 53% for imipenem, respectively). Seizures were observed more frequently with imipenem than with ciprofloxacin (6 versus 1%; P = 0.028). These results demonstrate that in patients with severe pneumonia, monotherapy with ciprofloxacin is at least equivalent to monotherapy with imipenem in terms of bacteriological eradication and clinical response. For both treatment groups, the presence of P. aeruginosa had a negative impact on treatment success. Seizures were more common with imipenem than with ciprofloxacin. Monotherapy for severe pneumonia is a safe and effective initial strategy but may need to be modified if P. aeruginosa is suspected or recovered from patients.

Full text

PDF
547

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arcieri G. M., Becker N., Esposito B., Griffith E., Heyd A., Neumann C., O'Brien B., Schacht P. Safety of intravenous ciprofloxacin. A review. Am J Med. 1989 Nov 30;87(5A):92S–97S. doi: 10.1016/0002-9343(89)90032-6. [DOI] [PubMed] [Google Scholar]
  2. Bayer A. S. Clinical utility of new quinolones in treatment of osteomyelitis and lower respiratory tract infections. Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1102–1110. doi: 10.1007/BF01975177. [DOI] [PubMed] [Google Scholar]
  3. Beam T. R., Jr, Gilbert D. N., Kunin C. M. General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S5–32. doi: 10.1093/clind/15.supplement_1.s5. [DOI] [PubMed] [Google Scholar]
  4. Celis R., Torres A., Gatell J. M., Almela M., Rodríguez-Roisin R., Agustí-Vidal A. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest. 1988 Feb;93(2):318–324. doi: 10.1378/chest.93.2.318. [DOI] [PubMed] [Google Scholar]
  5. Chastre J., Viau F., Brun P., Pierre J., Dauge M. C., Bouchama A., Akesbi A., Gibert C. Prospective evaluation of the protected specimen brush for the diagnosis of pulmonary infections in ventilated patients. Am Rev Respir Dis. 1984 Nov;130(5):924–929. doi: 10.1164/arrd.1984.130.5.924. [DOI] [PubMed] [Google Scholar]
  6. Chow A. W., Hall C. B., Klein J. O., Kammer R. B., Meyer R. D., Remington J. S. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S62–S88. doi: 10.1093/clind/15.Supplement_1.S62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Craig C. P., Connelly S. Effect of intensive care unit nosocomial pneumonia on duration of stay and mortality. Am J Infect Control. 1984 Aug;12(4):233–238. doi: 10.1016/0196-6553(84)90114-7. [DOI] [PubMed] [Google Scholar]
  8. Craven D. E., Kunches L. M., Kilinsky V., Lichtenberg D. A., Make B. J., McCabe W. R. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis. 1986 May;133(5):792–796. [PubMed] [Google Scholar]
  9. Fagon J. Y., Chastre J., Domart Y., Trouillet J. L., Pierre J., Darne C., Gibert C. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis. 1989 Apr;139(4):877–884. doi: 10.1164/ajrccm/139.4.877. [DOI] [PubMed] [Google Scholar]
  10. Fagon J. Y., Chastre J., Hance A. J., Guiguet M., Trouillet J. L., Domart Y., Pierre J., Gibert C. Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis. 1988 Jul;138(1):110–116. doi: 10.1164/ajrccm/138.1.110. [DOI] [PubMed] [Google Scholar]
  11. Faling L. J. New advances in diagnosing nosocomial pneumonia in intubated patients. Part I. Am Rev Respir Dis. 1988 Feb;137(2):253–255. doi: 10.1164/ajrccm/137.2.253. [DOI] [PubMed] [Google Scholar]
  12. Fernández-Guerrero M., Gudiol F., Rodriguez-Torres A., Arnau C., Valdés L., Vallvé C. Nosocomial pneumonia: comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations. Infection. 1991;19 (Suppl 6):S320–S325. doi: 10.1007/BF01715772. [DOI] [PubMed] [Google Scholar]
  13. Garber G. E., Auger P., Chan R. M., Conly J. M., Shafran S. D., Gerson M. A multicenter, open comparative study of parenteral cefotaxime and ceftriaxone in the treatment of nosocomial lower respiratory tract infections. Diagn Microbiol Infect Dis. 1992 Jan;15(1):85–88. doi: 10.1016/0732-8893(92)90061-w. [DOI] [PubMed] [Google Scholar]
  14. Gentry L. O., Rodriguez-Gomez G., Kohler R. B., Khan F. A., Rytel M. W. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Am Rev Respir Dis. 1992 Jan;145(1):31–35. doi: 10.1164/ajrccm/145.1.31. [DOI] [PubMed] [Google Scholar]
  15. Gleeson K., Reynolds H. Y. Pneumonia in the intensive care unit setting. J Intensive Care Med. 1992 Jan-Feb;7(1):24–35. doi: 10.1177/088506669200700104. [DOI] [PubMed] [Google Scholar]
  16. Gudiol F., Cabellos C., Pallares R., Linares J., Ariza J. Intravenous ciprofloxacin therapy in severe infections. Am J Med. 1989 Nov 30;87(5A):221S–224S. doi: 10.1016/0002-9343(89)90063-6. [DOI] [PubMed] [Google Scholar]
  17. Haley R. W., Culver D. H., White J. W., Morgan W. M., Emori T. G. The nationwide nosocomial infection rate. A new need for vital statistics. Am J Epidemiol. 1985 Feb;121(2):159–167. doi: 10.1093/oxfordjournals.aje.a113988. [DOI] [PubMed] [Google Scholar]
  18. Hartenauer U., Weilemann L. S., Bodmann K. F., Ritzerfeld W. W., Asmus S., Koch E. M. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J Hosp Infect. 1990 Apr;15 (Suppl A):61–64. doi: 10.1016/0195-6701(90)90081-x. [DOI] [PubMed] [Google Scholar]
  19. Hilf M., Yu V. L., Sharp J., Zuravleff J. J., Korvick J. A., Muder R. R. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989 Nov;87(5):540–546. doi: 10.1016/s0002-9343(89)80611-4. [DOI] [PubMed] [Google Scholar]
  20. Hirata-Dulas C. A., Stein D. J., Guay D. R., Gruninger R. P., Peterson P. K. A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections. J Am Geriatr Soc. 1991 Oct;39(10):979–985. doi: 10.1111/j.1532-5415.1991.tb04044.x. [DOI] [PubMed] [Google Scholar]
  21. Knaus W. A., Draper E. A., Wagner D. P., Zimmerman J. E. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818–829. [PubMed] [Google Scholar]
  22. LaForce F. M. Systemic antimicrobial therapy of nosocomial pneumonia: monotherapy versus combination therapy. Eur J Clin Microbiol Infect Dis. 1989 Jan;8(1):61–68. doi: 10.1007/BF01964122. [DOI] [PubMed] [Google Scholar]
  23. Leo R. J., Ballow C. H. Seizure activity associated with imipenem use: clinical case reports and review of the literature. DICP. 1991 Apr;25(4):351–354. doi: 10.1177/106002809102500403. [DOI] [PubMed] [Google Scholar]
  24. Leu H. S., Kaiser D. L., Mori M., Woolson R. F., Wenzel R. P. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am J Epidemiol. 1989 Jun;129(6):1258–1267. doi: 10.1093/oxfordjournals.aje.a115245. [DOI] [PubMed] [Google Scholar]
  25. Lode H., Wiley R., Höffken G., Wagner J., Borner K. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother. 1987 Oct;31(10):1491–1496. doi: 10.1128/aac.31.10.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. MANTEL N., HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed] [Google Scholar]
  27. Mangi R. J., Peccerillo K. M., Ryan J., Berenson C., Greco T., Thornton G., Andriole V. T. Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia. Diagn Microbiol Infect Dis. 1992 Jul;15(5):441–447. doi: 10.1016/0732-8893(92)90086-9. [DOI] [PubMed] [Google Scholar]
  28. Mangi R. J., Ryan J., Berenson C., Greco T., Simms M., 3rd, Thornton G., Andriole V. T. Cefoperazone versus ceftazidime monotherapy of nosocomial pneumonia. Am J Med. 1988 Jul 25;85(1A):44–48. doi: 10.1016/0002-9343(88)90174-x. [DOI] [PubMed] [Google Scholar]
  29. Martin C., Gouin F., Fourrier F., Junginger W., Prieur B. L. Pefloxacin in the treatment of nosocomial lower respiratory tract infections in intensive care patients. J Antimicrob Chemother. 1988 Jun;21(6):795–799. doi: 10.1093/jac/21.6.795. [DOI] [PubMed] [Google Scholar]
  30. Neu H. C., Labthavikul P. Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability. Antimicrob Agents Chemother. 1982 Jan;21(1):180–187. doi: 10.1128/aac.21.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Niederman M. S. Diagnosing nosocomial pneumonia: to brush or not to brush. J Intensive Care Med. 1991 Jul-Aug;6(4):151–152. doi: 10.1177/088506669100600401. [DOI] [PubMed] [Google Scholar]
  32. Niederman M. S., Ferranti R. D., Zeigler A., Merrill W. W., Reynolds H. Y. Respiratory infection complicating long-term tracheostomy. The implication of persistent gram-negative tracheobronchial colonization. Chest. 1984 Jan;85(1):39–44. doi: 10.1378/chest.85.1.39. [DOI] [PubMed] [Google Scholar]
  33. Pachon J., Prados M. D., Capote F., Cuello J. A., Garnacho J., Verano A. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis. 1990 Aug;142(2):369–373. doi: 10.1164/ajrccm/142.2.369. [DOI] [PubMed] [Google Scholar]
  34. Peloquin C. A., Cumbo T. J., Nix D. E., Sands M. F., Schentag J. J. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med. 1989 Oct;149(10):2269–2273. [PubMed] [Google Scholar]
  35. Potgieter P. D., Linton D. M., Forder A. A., Plumb H. Imipenem/cilastatin in the treatment of severe nosocomial pneumonia. S Afr Med J. 1988 Oct 15;74(8):390–392. [PubMed] [Google Scholar]
  36. Rapp R. P., Billeter M., Hatton J., Young A. B., Tibbs P. A., Dempsey R. J. Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. Clin Pharm. 1991 Jan;10(1):49–55. [PubMed] [Google Scholar]
  37. Rapp R. P., Young B., Bertch K., Tibbs P., Foster T. S. Clinical outcome of nosocomial pneumonia following imipenem/cilastatin therapy. Drug Intell Clin Pharm. 1987 Mar;21(3):272–276. doi: 10.1177/106002808702100308. [DOI] [PubMed] [Google Scholar]
  38. Richard C., Pezzano M., Bouhaja B., Rottman E., Rimailho A., Riou B., Auzepy P. Comparison of non-protected lower respiratory tract secretions and protected specimen brush samples in the diagnosis of pneumonia. Intensive Care Med. 1988;14(1):30–33. doi: 10.1007/BF00254118. [DOI] [PubMed] [Google Scholar]
  39. Rivera-Vazquez C. R., Ramirez-Ronda C. H., Rodriguez J. R., Saavedra S. A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections. Chemotherapy. 1989;35 (Suppl 1):89–100. doi: 10.1159/000238726. [DOI] [PubMed] [Google Scholar]
  40. Salata R. A., Gebhart R. L., Palmer D. L., Wade B. H., Scheld W. M., Groschel D. H., Wenzel R. P., Mandell G. L., Duma R. J. Pneumonia treated with imipenem/cilastatin. Am J Med. 1985 Jun 7;78(6A):104–109. doi: 10.1016/0002-9343(85)90110-x. [DOI] [PubMed] [Google Scholar]
  41. Torres A., Puig de la Bellacasa J., Rodriguez-Roisin R., Jimenez de Anta M. T., Agusti-Vidal A. Diagnostic value of telescoping plugged catheters in mechanically ventilated patients with bacterial pneumonia using the Metras catheter. Am Rev Respir Dis. 1988 Jul;138(1):117–120. doi: 10.1164/ajrccm/138.1.117. [DOI] [PubMed] [Google Scholar]
  42. Torres A., Puig de la Bellacasa J., Xaubet A., Gonzalez J., Rodríguez-Roisin R., Jiménez de Anta M. T., Agustí Vidal A. Diagnostic value of quantitative cultures of bronchoalveolar lavage and telescoping plugged catheters in mechanically ventilated patients with bacterial pneumonia. Am Rev Respir Dis. 1989 Aug;140(2):306–310. doi: 10.1164/ajrccm/140.2.306. [DOI] [PubMed] [Google Scholar]
  43. Torres A., Serra-Batlles J., Ferrer A., Jiménez P., Celis R., Cobo E., Rodriguez-Roisin R. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis. 1991 Aug;144(2):312–318. doi: 10.1164/ajrccm/144.2.312. [DOI] [PubMed] [Google Scholar]
  44. Trenholme G. M., Pottage J. C., Jr, Karakusis P. H. Use of ceftazidime in the treatment of nosocomial lower respiratory infections. Am J Med. 1985 Aug 9;79(2A):32–36. doi: 10.1016/0002-9343(85)90258-x. [DOI] [PubMed] [Google Scholar]
  45. Trenholme G. M., Schmitt B. A., Spear J., Gvazdinskas L. C., Levin S. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. Am J Med. 1989 Nov 30;87(5A):116S–118S. doi: 10.1016/0002-9343(89)90037-5. [DOI] [PubMed] [Google Scholar]
  46. Van Caekenberghe D. L., Pattyn S. R. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother. 1984 Apr;25(4):518–521. doi: 10.1128/aac.25.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wunderink R. G., Woldenberg L. S., Zeiss J., Day C. M., Ciemins J., Lacher D. A. The radiologic diagnosis of autopsy-proven ventilator-associated pneumonia. Chest. 1992 Feb;101(2):458–463. doi: 10.1378/chest.101.2.458. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES